Skip to main content
Spexis AG logo

Spexis AG — Investor Relations & Filings

Ticker · SPEX ISIN · CH0106213793 LEI · 391200S8HJE1I96FIG04 SW Manufacturing
Open in API
Filings indexed 194 across all filing types
Latest filing 2021-06-28 Regulatory Filings
Country CH Switzerland
Listing SW SPEX

About Spexis AG

https://www.polyphor.com/

Spexis AG is a clinical-stage biopharmaceutical company focused on discovering and developing therapeutics for rare diseases and oncology. The company leverages its expertise in macrocycle technology to create novel drug candidates designed to address high unmet medical needs. Its pipeline is advanced through a strategy that includes in-house discovery, development, in-licensing, and the acquisition of promising molecules. The primary therapeutic areas of interest include rare diseases and cancer, with an additional focus on antimicrobial resistance.

Recent filings

Filing Released Lang Actions
Polyphor provides update on the Phase III FORTRESS study of balixafortide in patients with advanced HER2 negative breast cancer
Regulatory Filings Classification · 98% confidence The document is explicitly labeled as an "Ad-hoc" announcement released on June 28, 2021, and states "Release of an ad hoc announcement pursuant to Art. 53 LR". It details the results of a Phase III clinical study (FORTRESS) for a drug (balixafortide) and mentions the board is undergoing a strategic assessment. This type of immediate, material, non-periodic disclosure by a listed company, especially one concerning clinical trial outcomes and strategic review, is typically classified as a general regulatory announcement or a specific material event disclosure. Since there is no specific category for 'Clinical Trial Results Announcement' and it is not a full financial report (10-K, IR), earnings release (ER), or management discussion (MDA), the most appropriate general regulatory category is 'Regulatory Filings' (RNS), as it is a mandatory disclosure of material, non-scheduled information.
2021-06-28 English
Polyphor Hosting Key Opinion Leader Roundtable on Covid-19: The Need for Novel Therapies for Severe Infections and the Potential Role of Balixafortide, a Selective CXCR4 Antagonist
Regulatory Filings Classification · 100% confidence The document is titled 'News Details' and is released as an 'Ad-hoc' announcement on June 8, 2021, pursuant to 'Art. 53 KR' (likely referring to Swiss regulatory requirements). The content announces that Polyphor AG will be hosting a 'Key Opinion Leader Roundtable' (a webinar) on a specific future date (June 10, 2021) to discuss Covid-19 therapies and their drug Balixafortide. This is not a formal financial report (like 10-K or IR), nor is it a transcript of a call that has already occurred. It is an announcement about an upcoming event involving key opinion leaders and management discussion, which aligns best with a general corporate communication or investor relations event announcement. Since it is an announcement about an upcoming event/presentation rather than a formal regulatory filing like a 10-K or an earnings release (ER), and it is not a transcript (CT), it falls under the general category of investor-related news. Given the options, this type of announcement about hosting a KOL event/webinar, which often serves as an informal update or presentation preview, is best categorized as an Investor Presentation (IP) if it were the presentation itself, or a general Regulatory Filing (RNS) if it's just the announcement. However, since it is announcing a specific event where management will discuss research findings and KOLs will present, it is closely related to investor communication. Since there is no specific code for 'Event Announcement', and it is a formal ad-hoc release, RNS (Regulatory Filings/General Announcement) is the most appropriate fallback for this type of corporate news release that doesn't fit the specific financial report codes.
2021-06-08 English
Polyphor's balixafortide demonstrates consistent dual action anti-viral and anti-inflammatory activity in COVID-19 preclinical trials
Regulatory Filings Classification · 95% confidence The document is explicitly labeled as an "Ad-hoc" announcement released on June 1, 2021, pursuant to Art. 53 KR (Kagis Regulation, common in Swiss markets). It details preclinical research results for a drug (balixafortide) related to COVID-19 and announces an upcoming conference call to discuss these results. This type of unscheduled, material information release, which is not a standard periodic report (like 10-K or IR) or a specific corporate action (like DIV or DIRS), fits best under the general category for regulatory announcements or miscellaneous filings that convey important, non-standard news. Since it is a specific research update and not a standard earnings release (ER) or a formal presentation (IP), and it doesn't fit other specific categories, the most appropriate classification is Regulatory Filings (RNS), which serves as a broad category for such ad-hoc disclosures not covered elsewhere.
2021-06-01 English
Polyphor to present at the UBS Global Healthcare Virtual Conference
Report Publication Announcement Classification · 99% confidence The document is a short announcement (4727 characters) dated May 18, 2021, titled 'Polyphor to present at the UBS Global Healthcare Virtual Conference'. It explicitly states it is an 'Ad-hoc' release and details a future event where company management will present. This structure—announcing participation in an external conference rather than releasing periodic financial results (ER/IR) or providing detailed internal reports (10-K/AR)—is characteristic of general investor relations updates. Since it is an announcement about an upcoming presentation/event, and not the presentation itself, it fits best under the general 'Regulatory Filings' (RNS) category as a standard corporate disclosure, or potentially an Investor Presentation (IP) if the linked material was the presentation itself, but the text is purely an announcement of attendance. Given the nature of the announcement (conference participation), RNS is the most appropriate general regulatory disclosure category.
2021-05-18 English
Polyphor Annual General Meeting 2021
AGM Information Classification · 99% confidence The document explicitly discusses the 'Polyphor Annual General Meeting 2021' and details the outcomes of shareholder votes, including the re-election of board members and the approval of financial statements for 2020. The title and content directly relate to the proceedings and results of an Annual General Meeting (AGM). This aligns perfectly with the definition for AGM Information (AGM-R). Although it mentions the approval of financial statements, the primary focus is the meeting itself, not the release of the full 10-K or IR.
2021-04-06 English
Polyphor publishes invitation to Annual General Meeting 2021
AGM Information Classification · 99% confidence The document is explicitly titled "Polyphor publishes invitation to Annual General Meeting 2021". It details the date of the AGM (April 6, 2021), mentions a pre-AGM information call, and discusses conducting the meeting without physical shareholder presence due to COVID-19 ordinances. This content directly relates to the preparation and announcement of the Annual General Meeting. Therefore, the appropriate classification is AGM Information (AGM-R). The document length (5704 chars) is substantial enough that it is not merely a brief announcement of a report (RPA/RNS), but the core information regarding the meeting itself.
2021-03-15 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.